- Prescient Therapeutics (PTX) opens patient enrolments for an expanded phase 1B trial of its PTX-100 therapy to treat T-cell lymphomas, a group of aggressive and rare blood cancers
- The company is looking to recruit eight to 12 patients suffering relapsed and refractory T-cell lymphoma for the study, which will be led by world-renowned hematologist Professor H. Miles Prince at Epworth Hospital in Melbourne
- Prescient says “excellent” safety data and encouraging preliminary evidence of clinical efficacy in patients with T-cell lymphomas in the original phase 1b study prompted clinical investigators to recommend expanding the study and enrolling patients with peripheral T-cell lymphomas (PTCL)
- Prescient says it is still aiming to complete recruitment of the expansion cohort by the end of 2022
- PTX shares steady at 15 cents
Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its PTX-100 therapy to treat T-cell lymphomas, a group of aggressive and rare blood cancers.
The company said it is looking to recruit eight to 12 patients suffering relapsed and refractory T-cell lymphoma for the study, which will be led by world-renowned hematologist Professor H. Miles Prince at Epworth Hospital in Melbourne.
Prescient said “excellent” safety data and encouraging preliminary evidence of clinical efficacy in patients with T-cell lymphomas in the original phase 1b study prompted clinical investigators to recommend expanding the study and enrolling patients with peripheral T-cell lymphomas (PTCL).
One PTCL patient from the initial phase 1b trial who had undergone 37 cycles of therapy and failed five prior therapies, experienced a partial response (a noted reduction in cancer burden) when treated with PTX-100, according to the company.
The response has endured for 24 months so far, Prescient said.
“We continue to be encouraged by the safety and clinical activity of PTX-100 in patients with T-cell lymphomas,” Professor Prince said.
“We look forward to expanding the investigations of PTX-100 in T-cell lymphomas, where we have already seen two unexpected and stunning responses in the prior cohort.
“It would be very exciting to see further responses to PTX-100 in this expansion cohort, particularly in PTCL, which is an aggressive cancer with few effective treatment options.”
Prescient said the PTX-100 drug shipment had arrived in Australia to support the trials and it was aiming to complete recruitment of the expansion cohort by the end of 2022.
The company planned to also include patients with cutaneous T-cell lymphoma (CTCL) in the expanded phase 1b study and said the clinical samples would bolster insights on drug activity in T-cell lymphomas overall.
PTX shares were steady at 15 cents at 2:10 pm AEST.